Publikationen

 

2011

 

Mohr F, Döhner K, Buske C, et al. TET genes: New players in DNA demethylation and important determinants for stemness. Exp Hematol 2011; 39 (3): 272 - 281.

 

Eppert K, Takenaka K, Lechman ER, et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nature Medicine (in press).

 

Kuchenbauer F, Mah SM, Heuser M, et al. Comprehensive analysis of mammalian miRNA* species and their role in myeloid cells. Blood (in press).

 

Deshpande AJ, Rouhi A, Lin Y, et al. The clathrin binding domain of CALM and OM-LZ domain of AF10 are sufficient to induce acute myeloid leukemia in mice. Leukemia (in press).

 

Herold T, Jurinovic V, Mulaw M, et al. Expression analysis of genes located in the minimally deleted regions of 13q14 and 11q22-23 in chronic lymphocytic leukemia-unexpected experssion pattern of the RHO GTPase activator ARHGAP20.  Leukemia (in press).

 

Herold T, Jurinovic V, Metzeler KH, et al. An 8 gene expression signature for the prediction of survival and time to treatment in chronic lymphocytic leukemia. Leukemia (in press).

 

Aniruddha J, Desphande A, Rouhi A, et al. The OM-LZ domain and the clathrin binding domain of CALM-AF10 are sufficient to induce acute myeloid leukemia in mice. Leukemia (in press).

 

2010

 

Rawat VP, Arseni N, Ahmed F, et al. The vent-like homeobox gene VENTX promotes human myeloid differentiation and is highly expressed in acute myeloid leukemia. Proc Natl Acad Sci U S A. 2010.

 

Petri OI, Kuchenbauer F, Delaney AD, et al. Comprehensive microRNA expression profiling of the hematopoietic hierarchy. Proc Natl Acad Sci U S A. 2010.

Buske C. Hematologic malignancies-sixth European congress. 26-28 February 2010, Cannes, France. Drugs 2010;13:300-303.

 

Buske C. Indolent lymphoma in the elderly. Proceedings of the first international conference on Haematological Malignancies in the Elderley. Lissabon, Portugal, 2010; 5: 67-68.

 

Mah SM, Buske C. Humphries RK, Kuchenbauer F. miRNA: A passenger stranded in RNA-induced silencing complex? Crit Rev Eukariot Gene Expr 2010; 20(2): 141-148. Review.

 

Schöler N, Langer C, Döhner H, Buske C, Kuchenbauer F. Serum microRNAs as a novel class of biomarkers: a comprehensive review of the literature. Exp Hematol 2010; 38(12): 1126-30. Review.

 

2009

 

Rao AV, Valk PJ, Metzeler KH, et al. Age-specific differences in oncogenic pathway dysregulation and anthracycline sensitivity in patients with acute myeloid leukemia. J Clin Oncol. 2009;27:5580-5586.

Deshpande A, Pastore A, Deshpande AJ, et al. 3'UTR mediated regulation of the cyclin D1 proto-oncogene. Cell Cycle. 2009;8:3584-3592.

Metzeler KH, Dufour A, Benthaus T, et al. ERG expression is an independent prognostic factor and allows refined risk stratification in cytogenetically normal acute myeloid leukemia: a comprehensive analysis of ERG, MN1, and BAALC transcript levels using oligonucleotide microarrays. J Clin Oncol. 2009;27:5031-5038.

Deshpande AJ, Ahmed F, Buske C. Identification of murine and human acute myeloid leukemia stem cells. Methods Mol Biol. 2009;568:21-35.

Heilmeier B, Spiekermann K, Bohlander S, et al. [Modern leukemia diagnosis in adults]. Dtsch Med Wochenschr. 2009;134:1222-1226.

Lin YH, Kakadia PM, Chen Y, et al. Global reduction of the epigenetic H3K79 methylation mark and increased chromosomal instability in CALM-AF10-positive leukemias. Blood. 2009;114:651-658.

Schneider F, Hoster E, Unterhalt M, et al. NPM1 but not FLT3-ITD mutations predict early blast cell clearance and CR rate in patients with normal karyotype AML (NK-AML) or high-risk myelodysplastic syndrome (MDS). Blood. 2009;113:5250-5253.

Reindl C, Quentmeier H, Petropoulos K, et al. CBL exon 8/9 mutants activate the FLT3 pathway and cluster in core binding factor/11q deletion acute myeloid leukemia/myelodysplastic syndrome subtypes. Clin Cancer Res. 2009;15:2238-2247.

Thoene S, Rawat VP, Heilmeier B, et al. The homeobox gene CDX2 is aberrantly expressed and associated with an inferior prognosis in patients with acute lymphoblastic leukemia. Leukemia. 2009;23:649-655.

Braess J, Spiekermann K, Staib P, et al. Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG. Blood. 2009;113:3903-3910.

Buske C, Hoster E, Dreyling M, et al. The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). Leukemia. 2009;23:153-161.

 

2008

 

Buske C, Gisselbrecht C, Gribben J, Letai T, McLaughlin P, Wilson W. Refining the treatment of follicular lymphoma. Leuk Lymphoma. 2008;49 Suppl 1:18-26.

Archangelo LF, Greif PA, Holzel M, et al. The CALM and CALM/AF10 interactor CATS is a marker for proliferation. Mol Oncol. 2008;2:356-367.

Metzeler KH, Hummel M, Bloomfield CD, et al. An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia. Blood. 2008;112:4193-4201.

Vempati S, Reindl C, Wolf U, et al. Transformation by oncogenic mutants and ligand-dependent activation of FLT3 wild-type requires the tyrosine residues 589 and 591. Clin Cancer Res. 2008;14:4437-4445.

Petropoulos K, Arseni N, Schessl C, et al. A novel role for Lef-1, a central transcription mediator of Wnt signaling, in leukemogenesis. J Exp Med. 2008;205:515-522.

Ahmed F, Arseni N, Glimm H, Hiddemann W, Buske C, Feuring-Buske M. Constitutive expression of the ATP-binding cassette transporter ABCG2 enhances the growth potential of early human hematopoietic progenitors. Stem Cells. 2008;26:810-818.

Rawat VP, Thoene S, Naidu VM, et al. Overexpression of CDX2 perturbs HOX gene expression in murine progenitors depending on its N-terminal domain and is closely correlated with deregulated HOX gene expression in human acute myeloid leukemia. Blood. 2008;111:309-319.

 

2007

 

Schmitz N, Buske C, Gisselbrecht C. Autologous stem cell transplantation in lymphoma. Semin Hematol. 2007;44:234-245.

Deshpande AJ, Buske C. Knocking the Wnt out of the sails of leukemia stem cell development. Cell Stem Cell. 2007;1:597-598.

Buske C, Hiddemann W. [The older patient with malignant diseases]. Internist (Berl). 2007;48:1206,1208-1210.

Metzeler KH, Braess J, Spiekermann K, et al. [Fortuitous finding: thrombocytopenia and thrombocytosis]. MMW Fortschr Med. 2007;149:34-35, 37.

Schneider F, Bohlander SK, Schneider S, et al. AML1-ETO meets JAK2: clinical evidence for the two hit model of leukemogenesis from a myeloproliferative syndrome progressing to acute myeloid leukemia. Leukemia. 2007;21:2199-2201.

Kohl TM, Hellinger C, Ahmed F, et al. BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts. Leukemia. 2007;21:1763-1772.

Fritsch S, Buske C, Wormann B, Wedding U, Hiddemann W, Spiekermann K. [Therapy of acute myeloid leukemia (AML) for medically non-fit patients]. Med Klin (Munich). 2007;102:324-329.

Heilmeier B, Buske C, Spiekermann K, et al. [Diagnostics, classification and prognostic criteria of acute myeloid leukemia]. Med Klin (Munich). 2007;102:296-308.

Christ O, Feuring-Buske M, Hiddemann W, Buske C. [Pathobiology of acute myeloid leukemia]. Med Klin (Munich). 2007;102:290-295.

Buske C, Hiddemann W. [Malignant lymphoma--there are still many open questions]. Internist (Berl). 2007;48:349-350.

Deshpande AJ, Buske C. Lymphoid progenitors as candidate cancer stem cells in AML: new perspectives. Cell Cycle. 2007;6:543-545.

Buske C, Unterhalt M, Hiddeman W. [Therapy of follicular lymphoma]. Internist (Berl). 2007;48:372-381.

Hiddemann W, Buske C, Dreyling M, Weigert O, Lenz G, Unterhalt M. Current management of follicular lymphomas. Br J Haematol. 2007;136:191-202.

 

2006

 

Deshpande AJ, Cusan M, Rawat VP, et al. Acute myeloid leukemia is propagated by a leukemic stem cell with lymphoid characteristics in a mouse model of CALM/AF10-positive leukemia. Cancer Cell. 2006;10:363-374.

Fritsch S, Metzeler K, Hiddemann W, Buske C. [Diagnostics and therapy of acute myeloid leukemia]. Dtsch Med Wochenschr. 2006;131:2401-2406.

Kuchenbauer F, Schnittger S, Look T, et al. Identification of additional cytogenetic and molecular genetic abnormalities in acute myeloid leukaemia with t(8;21)/AML1-ETO. Br J Haematol. 2006;134:616-619.

Weigert O, Dreyling M, Unterhalt M, Hiddemann W, Buske C. Investigational strategies in autologous stem cell transplantation for follicular lymphoma. Curr Oncol Rep. 2006;8:368-375.

Metzeler K, Fritsch S, Buske C, Hiddemann W. [Acute myeloid leukemia -- on the way towards pathogenesis-oriented treatment]. Dtsch Med Wochenschr. 2006;131:1466-1468.

Hiddemann W, Spiekermann K, Braess J, Feuring-Buske M, Buske C, Buchner T. [Risk-adapted therapy of acute myeloid leukemia]. Internist (Berl). 2006;47 Suppl 1:S33-39.

Buske C, Hiddemann W. Rituximab maintenance therapy in indolent NHL: a clinical review. Leuk Res. 2006;30 Suppl 1:S11-15.

Buske C, Hoster E, Dreyling M, Hasford J, Unterhalt M, Hiddemann W. The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood. 2006;108:1504-1508.

Buske C, Glimm H, Feuring-Buske M. [Stem cell therapy. Biology of hematopoietic stem cells]. Internist (Berl). 2006;47:459-460, 462-454.

Buske C, Weigert O, Dreyling M, Unterhalt M, Hiddemann W. Current status and perspective of antibody therapy in follicular lymphoma. Haematologica. 2006;91:104-112.

Feuring-Buske M, Hartmann EM, Ott G, Reuter H, Buske C, Rosenwald A. [DNA-chips in the diagnosis of hematological malignancies]. Internist (Berl). 2006;47:39-46.

2005

 

Kuchenbauer F, Feuring-Buske M, Buske C. AML1-ETO needs a partner: new insights into the pathogenesis of t(8;21) leukemia. Cell Cycle. 2005;4:1716-1718.

Arseni N, Ahmed F, Hiddemann W, Buske C, Feuring-Buske M. Effects of the protein tyrosine kinase inhibitor, SU5614, on leukemic and normal stem cells. Haematologica. 2005;90:1577-1578.

Hiddemann W, Spiekermann K, Buske C, et al. Towards a pathogenesis-oriented therapy of acute myeloid leukemia. Crit Rev Oncol Hematol. 2005;56:235-245.

Dreyling M, Buske C, Hiddemann W. [Up-to-date treatment of follicular lymphomas]. Dtsch Med Wochenschr. 2005;130:2149-2154.

Hiddemann W, Buske C, Dreyling M, et al. Treatment strategies in follicular lymphomas: current status and future perspectives. J Clin Oncol. 2005;23:6394-6399.

Schessl C, Rawat VP, Cusan M, et al. The AML1-ETO fusion gene and the FLT3 length mutation collaborate in inducing acute leukemia in mice. J Clin Invest. 2005;115:2159-2168.

Dreyling M, Buske C, Hiddemann W. Advances in molecular biology diagnostic and treatment of B-cell malignancies: indolent B-cell lymphoma. Ann Oncol. 2005;16 Suppl 2:ii99-104.

Buske C, Dreyling M, Unterhalt M, Hiddemann W. Transplantation strategies for patients with follicular lymphoma. Curr Opin Hematol. 2005;12:266-272.

Buske C, Dreyling M, Unterhalt M, Hiddemann W. [Monoclonal antibody therapy for malignant lymphoma]. Med Klin (Munich). 2005;100:14-24. 

2004- 2000

 

Buske C, Dreyling M, Unterhalt M, Hiddemann W. [Monoclonal antibody treatment of malignant lymphoma]. Internist (Berl). 2004;45:1370-1377.

Buske C, Dreyling H, Unterhalt M, Hiddemann W. Novel treatment strategies in follicular lymphoma. Ann Hematol. 2004;83 Suppl 1:S72.

Rawat VP, Cusan M, Deshpande A, et al. Ectopic expression of the homeobox gene Cdx2 is the transforming event in a mouse model of t(12;13)(p13;q12) acute myeloid leukemia. Proc Natl Acad Sci U S A. 2004;101:817-822.

Pineault N, Buske C, Feuring-Buske M, et al. Induction of acute myeloid leukemia in mice by the human leukemia-specific fusion gene NUP98-HOXD13 in concert with Meis1. Blood. 2003;101:4529-4538.

Spiekermann K, Dirschinger RJ, Schwab R, et al. The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3. Blood. 2003;101:1494-1504.

Feuring-Buske M, Hiddemann W, Buske C. [Pathogenesis and biology of leukemias]. Internist (Berl). 2002;43:1179-1189.

Buske C, Hiddemann W. [Acute and chronic leukemias. Current aspects of pathogenesis, diagnosis and therapy]. Internist (Berl). 2002;43:1177-1178.

Buske C, Feuring-Buske M, Abramovich C, et al. Deregulated expression of HOXB4 enhances the primitive growth activity of human hematopoietic cells. Blood. 2002;100:862-868.

Blaschke S, Hannig H, Buske C, Kaup FJ, Hunsmann G, Bodemer W. Expression of the simian Epstein-Barr virus-encoded latent membrane protein-1 in malignant lymphomas of SIV-infected rhesus macaques. J Med Virol. 2001;65:114-120.

Buske C, Feuring-Buske M, Antonchuk J, et al. Overexpression of HOXA10 perturbs human lymphomyelopoiesis in vitro and in vivo. Blood. 2001;97:2286-2292.

Buske C, Humphries RK. Homeobox genes in leukemogenesis. Int J Hematol. 2000;71:301-308.